Emodin, an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, regulates adipocyte function in vitro and exerts anti-diabetic effect in ob/ob mice

Acta Pharmacologica Sinica

Volumn 33, Issue 9, 2012, Pages 1195-1203

  Wang, Yue Jing ^a   Huang, Su Ling ^a   Feng, Ying ^a   Ning, Meng Meng ^a   Leng, Ying ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

11 hydroxysteroid dehydrogenase type 1; adipocyte; emodin; glucocorticoid; ob ob mice; type 2 diabetes

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 1A; ADIPONECTIN; ANTIDIABETIC AGENT; CORTICOSTERONE; DEHYDROCORTICOSTERONE; EMODIN; GLUCOSE; INSULIN; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIPOLYSIS; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PROTEIN SECRETION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EMODIN; ENZYME INHIBITORS; GLUCOCORTICOIDS; HYPOGLYCEMIC AGENTS; INHIBITORY CONCENTRATION 50; INSULIN; LIPOLYSIS; MICE; MICE, OBESE; TIME FACTORS;

EID: 84865972133     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.87     Document Type: Article

References (32)

1. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006; 444: 847-53. (Pubitemid 46024991)
2. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 367-77. (Pubitemid 351574198)
3. Beauregard C, Dickstein G, Lacroix A. Classic and recent etiologies of Cushing's syndrome: diagnosis and therapy. Treat Endocrinol 2002; 1: 79-94. (Pubitemid 36828428)
4. Seckl JR, Walker BR. Minireview: 11beta-hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001; 142: 1371-6. (Pubitemid 32299662)
5. Morton NM. Obesity and corticosteroids: 11beta-hydroxysteroid type 1. as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol 2010; 316: 154-64.
6. Hollis G, Huber R. 11beta-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus. Diabetes Obes Metab 2011; 13: 1-6.
7. Westerbacka J, Yki-Jarvinen H, Vehkavaara S, Hakkinen AM, Andrew R, Wake DJ, et al. Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J Clin Endocrinol Metab 2003; 88: 4924-31. (Pubitemid 37357545)
8. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-70. (Pubitemid 33150673)
9. Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003; 112: 83-90. (Pubitemid 38056379)
10. Paterson JM. Metabolic syndrome without obesity: Hepatic overexpression of 11-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A 2004; 101: 7088-93. (Pubitemid 38596447)
11. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, et al. 11Beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A 1997; 94: 14924-9. (Pubitemid 28041476)
12. Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ, et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 2001; 276: 41293-300.
13. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004; 53: 931-8. (Pubitemid 38436604)
14. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, Flier JS. Adipocyte-specific glucocorticoid inactivation protects against dietinduced obesity. Diabetes 2005; 54: 1023-31. (Pubitemid 40446315)
15. Wang HH, Chung JG. Emodin-induced inhibition of growth and DNA damage in the Helicobacter pylori. Curr Microbiol 1997; 35: 262-6.
16. Huang Q, Lu G, Shen HM, Chung MC, Ong CN. Anti-cancer properties of anthraquinones from rhubarb. Med Res Rev 2007; 27: 609-30. (Pubitemid 47282446)
17. Chang CH, Lin CC, Yang JJ, Namba T, Hattori M. Anti-inflammatory effects of emodin from ventilago leiocarpa. Am J Chin Med 1996; 24: 139-42. (Pubitemid 126765683)
18. Huang HC, Chang JH, Tung SF, Wu RT, Foegh ML, Chu SH. Immunosuppressive effect of emodin, a free radical generator. Eur J Pharmacol 1992; 211: 359-64.
19. Woo SW, Nan JX, Lee SH, Park EJ, Zhao YZ, Sohn DH. Aloe emodin suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Pharmacol Toxicol 2002; 90: 193-8. (Pubitemid 34478340)
20. Heo SK, Yun HJ, Park WH, Park SD. Emodin inhibits TNF-alphainduced human aortic smooth-muscle cell proliferation via caspaseand mitochondrial-dependent apoptosis. J Cell Biochem 2008; 105: 70-80.
21. Feng Y, Huang SL, Dou W, Zhang S, Chen JH, Shen Y, et al. Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice. Br J Pharmacol 2010; 161: 113-26.
22. Hu X, Feng Y, Liu X, Zhao XF, Yu JH, Yang YS, et al. Effect of a novel non-thiazolidinedione peroxisome proliferator-activated receptor alpha/gamma agonist on glucose uptake. Diabetologia 2007; 50: 1048-57. (Pubitemid 46559258)
23. Hewitt KN, Walker EA, Stewart PM. Minireview: hexose-6-phosphate dehydrogenase and redox control of 11{beta}-hydroxysteroid dehydrogenase type 1 activity. Endocrinology 2005; 146: 2539-43. (Pubitemid 40695555)
24. Seckl JR, Morton NM, Chapman KE, Walker BR. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res 2004; 59: 359-93.
25. Kim J, Temple KA, Jones SA, Meredith KN, Basko JL, Brady MJ. Differential modulation of 3T3-L1 adipogenesis mediated by 11betahydroxysteroid dehydrogenase-1 levels. J Biol Chem 2007; 282: 11038-46. (Pubitemid 47100791)
26. Sakoda H, Ogihara T, Anai M, Funaki M, Inukai K, Katagiri H, et al. Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction. Diabetes 2000; 49: 1700-8.
27. Divertie GD, Jensen MD, Miles JM. Stimulation of lipolysis in humans by physiological hypercortisolemia. Diabetes 1991; 40: 1228-32.
28. Shi JH, Du WH, Liu XY, Fan YP, Hu XL, Zhou HY, et al. Glucocorticoids decrease serum adiponectin level and WAT adiponectin mRNA expression in rats. Steroids 2010; 75: 853-8.
29. Herberg L, Leiter EH, editor. Obesity/diabetes in mice with mutations in the leptin or leptin receptor genes. Amsterdam Harwood Academic 2001.
30. Cavagnini F, Croci M, Putignano P, Petroni ML, Invitti C. Glucocorticoids and neuroendocrine function. Int J Obes Relat Metab Disord 2000; 24: S77-9. (Pubitemid 30461954)
31. Wang SJ, Birtles S, de Schoolmeester J, Swales J, Moody G, Hislop D, et al. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetologia 2006; 49: 1333-7.
32. Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004; 53: S43-50. (Pubitemid 38168692)